| Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma KY Aguilera, H Huang, W Du, MM Hagopian, Z Wang, S Hinz, TH Hwang, ... Molecular cancer therapeutics 16 (11), 2473-2485, 2017 | 112 | 2017 |
| Hypoxia Studies with Pimonidazole in vivo KY Aguilera, RA Brekken Bio-protocol 4 (19), e1254-e1254, 2014 | 106 | 2014 |
| Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma KY Aguilera, LB Rivera, H Hur, JG Carbon, JE Toombs, CD Goldstein, ... Cancer research 74 (4), 1032-1044, 2014 | 105 | 2014 |
| Recruitment and retention: factors that affect pericyte migration KY Aguilera, RA Brekken Cellular and Molecular Life Sciences 71, 299-309, 2014 | 92 | 2014 |
| SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations F Mateo, Ó Meca-Cortés, T Celià-Terrassa, Y Fernández, I Abasolo, ... Molecular cancer 13, 1-17, 2014 | 81 | 2014 |
| Lipid metabolism in Giardia: a post-genomic perspective M Yichoy, TT Duarte, A De Chatterjee, TL Mendez, KY Aguilera, D Roy, ... Parasitology 138 (3), 267-278, 2011 | 75 | 2011 |
| Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma H Hur, IH Ham, D Lee, H Jin, KY Aguilera, HJ Oh, SU Han, JE Kwon, ... BMC cancer 17, 1-11, 2017 | 60 | 2017 |
| WNT ligand dependencies in pancreatic cancer KY Aguilera, DW Dawson Frontiers in cell and developmental biology 9, 671022, 2021 | 55 | 2021 |
| Combination of bemcentinib (BGB324): a first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung M Yule, K Davidsen, M Bloe, L Hodneland, A Engelsen, M Lie, ... J Clin Oncol 36 (5_suppl), TPS43-TPS43, 2018 | 15 | 2018 |
| Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand–Addicted Pancreatic Cancer KY Aguilera, T Le, R Riahi, AR Lay, S Hinz, EA Saadat, AA Vashisht, ... Molecular cancer therapeutics 21 (6), 936-947, 2022 | 8 | 2022 |
| BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint … K Wnuk-Lipinska, K Davidsen, M Blø, A Engelsen, J Kang, L Hodneland, ... Cancer Research 77 (13_Supplement), 626-626, 2017 | 7 | 2017 |
| Deep proteome profiling of human mammary epithelia at lineage and age resolution S Hinz, A Manousopoulou, M Miyano, RW Sayaman, KY Aguilera, ... Iscience 24 (9), 2021 | 6 | 2021 |
| Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof RA Brekken, K Ding, REN Xiaomei, TU Zhengchao, Z Wang, ... | 6 | 2016 |
| dynamic changes in circulating tumor DNA (ctDNA) in patients treated with sotorasib for KRAS G12C mutant non-small cell lung cancer YR Murciano-Goroff, F Skoulidis, V Velcheti, GS Falchook, G Dy, ... Cancer Research 83 (7_Supplement), 1144-1144, 2023 | 5 | 2023 |
| 40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC DM Waterhouse, S Rothschild, C Dooms, B Mennecier, F Bozorgmehr, ... Journal of Thoracic Oncology 18 (4), S37-S38, 2023 | 5 | 2023 |
| OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models J Estrada, J Zhan, P Mitchell, J Werner, PJ Beltran, J DeVoss, J Qing, ... Journal for Immunotherapy of Cancer 11 (5), 2023 | 4 | 2023 |
| BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy K Davidsen, K Wnuk-Lipinska, W Du, M Blø, A Engelsen, S Terry, ... Cancer Research 78 (13_Supplement), 3774-3774, 2018 | 4 | 2018 |
| Collagen Signaling in Cancer H Huang, ME Kovacs, KY Aguilera, RA Brekken Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy, 89-108, 2019 | 3 | 2019 |
| SPARC as a regulator of collagen signaling in pancreatic cancer KY Aguilera, CD Goldstein, LB Rivera, AD Bradshaw, K Ding, RA Brekken Cancer Research 74 (19_Supplement), 182-182, 2014 | 3 | 2014 |
| A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced … L Moreno, P Teira, JM Croop, NU Gerber, N André, I Aerts, L Gros Subias, ... Frontiers in Pediatrics 11, 1183295, 2023 | 2 | 2023 |